
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
Key Takeaways
- Accelerated approval covers two distinct post-treatment populations, requiring careful verification of prior ALK TKI sequence and platinum chemotherapy exposure in the advanced/metastatic setting.
- Neladalkib (NVL-655) was engineered for ALK resistance coverage, CNS penetration, and TRK-sparing selectivity, including preclinical activity against compound mutations linked to lorlatinib resistance.
Neladalkib received accelerated approval for adults with advanced ALK-positive NSCLC after specified prior therapies, supported by durable responses in the ALKOVE-1 trial.
The FDA granted accelerated approval to neladalkib (Nelkarmi; Nuvalent, Inc.) on November 17, 2026, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) following specified prior treatments. The once-daily oral kinase inhibitor offers an additional targeted option for eligible patients with previously treated disease.¹
The indication covers patients who received either alectinib as their only prior ALK tyrosine kinase inhibitor (TKI), or at least 2 prior ALK TKIs and platinum-based chemotherapy. These treatments must have been administered in the unresectable locally advanced or metastatic setting.¹
For pharmacists reviewing treatment plans, the distinction matters: eligibility depends on the specific treatment history, including prior chemotherapy in the more heavily pretreated group.¹
A Targeted Approach to ALK Resistance
Neladalkib, previously known as NVL-655, was developed as an ALK-selective inhibitor designed to address resistance to earlier ALK-directed therapies. Its development also focused on brain penetration and avoiding inhibition of tropomyosin receptor kinases (TRK).²
Preclinical characterization and early clinical observations supported activity against ALK resistance mutations, including compound mutations associated with resistance to lorlatinib. These findings provided the rationale for evaluating neladalkib in patients whose cancers had already been exposed to ALK inhibitors. They do not establish comparative clinical superiority over other approved treatments.²
ALKOVE-1 Shows Responses Across Both Approved Populations
The approval was supported by ALKOVE-1 (NCT05384626), a multicenter, single-arm, open-label, multicohort trial. The phase 1/2 program evaluated neladalkib’s safety and tolerability, established a recommended phase 2 dose, and assessed antitumor activity in ALK-positive cancers.¹˒³
The FDA’s efficacy evaluation included 67 patients previously treated with alectinib as their only ALK TKI in the metastatic setting and 155 patients previously treated with at least 2 ALK TKIs and platinum-based chemotherapy. Confirmed overall response rate (ORR) and duration of response (DOR) were assessed by blinded independent central review using RECIST version 1.1.¹
In the prior-alectinib group, ORR was 49% (95% CI, 37%-62%). Among responding patients, 76% had a DOR of at least 6 months and 52% had a DOR of at least 12 months.¹
In the more heavily pretreated group, ORR was 32% (95% CI, 24%-40%). Among responders, 69% had a DOR of at least 6 months and 51% had a DOR of at least 12 months. These durability percentages describe responding patients rather than all patients in each efficacy population.¹
Because ALKOVE-1 was single-arm, the reported results do not establish an efficacy advantage over another ALK inhibitor or chemotherapy. The differing treatment histories also limit direct comparisons between the 2 groups.¹
Dosing and Safety Considerations for Pharmacists
The recommended dose is 150 mg orally once daily, taken at the same time each day with or without food. Treatment continues until disease progression or unacceptable toxicity.¹
Warnings and precautions include hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. Adverse reactions occurring in at least 20% of patients included hepatotoxicity and musculoskeletal pain, along with constipation, dysgeusia, peripheral neuropathy, edema, and fatigue.¹
These risks give pharmacists several priorities when preparing patients for therapy. Counseling can reinforce consistent daily administration and encourage early reporting of vision changes or worsening muscle symptoms. Patients should also understand that new or worsening neuropathy, constipation, or swelling warrants discussion with the oncology team. The embryo-fetal toxicity warning makes reproductive counseling another component of treatment preparation.¹
Medication reconciliation and an individualized monitoring plan should accompany initiation. Pharmacists should consult the full prescribing information for laboratory monitoring schedules, interaction management, and dose modifications as it becomes available through Drugs@FDA.¹
Accelerated Approval Requires Confirmation of Benefit
The decision was based on tumor response and response durability. Under the FDA’s accelerated approval pathway, additional studies are required to confirm anticipated clinical benefit; response findings alone do not demonstrate longer survival.¹˒⁴
The application received priority review, and neladalkib previously received breakthrough therapy and orphan drug designations. For eligible patients, the approval adds another treatment option after the prior regimens specified in the indication.¹
REFERENCES
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. FDA. November 17, 2026. Accessed November 17, 2026.
https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk?utm_medium=email&utm_source=govdelivery Nuvalent announces publication in Cancer Discovery detailing design and characterization of ALK-selective inhibitor NVL-655. News release. Nuvalent, Inc. September 13, 2024. Accessed November 17, 2026.
2024-09-13-Nuvalent-Announces-Publication-in-Cancer-Discovery-Detailing-Design-and-Characterization-of-ALK-selective-inhibitor-NVL-655 A study of NVL-655 in patients with advanced NSCLC and other solid tumors harboring ALK rearrangement or activating ALK mutation (ALKOVE-1). UC Davis Health. Updated November 4, 2026. Accessed November 17, 2026.
A-study-of-nvl-655-in-patients-with-advanced-nsclc-and-other-solid-tumors-harboring-alk-rearrangement-or-activating-alk-mutation-alkove-1-280802 Accelerated Approval Program. FDA. Accessed November 17, 2026.
https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program
Related to this article








